Sucampo Pharmaceuticals

From WikiProjectMed
Jump to navigation Jump to search
Sucampo Pharmaceuticals, Inc.
IndustryPharmaceutical industry
Founded1996; 28 years ago (1996)
DefunctFebruary 12, 2018; 6 years ago (2018-02-12)
FateAcquired by Mallinckrodt
HeadquartersRockville, Maryland
Key people
Peter Greenleaf (CEO and (Chairman)
Andrew P. Smith (CFO)
ProductsAmitiza
RevenueIncrease $230 million (2016)
Decrease $18 million (2016)
Total assetsIncrease $520 million (2016)
Total equityIncrease $167 million (2016)
Number of employees
139 (2017)
Websitewww.sucampo.com Edit this on Wikidata
Footnotes / references
[1]

Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders.[1] In 2018, the company was acquired by Mallinckrodt.

Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had a license to distribute Rescula globally except for in Japan and China. The company had two Phase III drugs in development for rare diseases — one for Niemann-Pick Type C and the other for familial adenomatous polyposis, which can cause colon cancer if untreated.[1]

History

The company was founded by Ryuji Ueno and Sachiko Kuno in 1996.[1]

In January 2006, the company received approval from the Food and Drug Administration for Amitiza.[2]

In 2010, the company entered into arbitration with its partner, Takeda Pharmaceutical Company, claiming that sales of Amitiza floundered because of a half-hearted marketing effort by Takeda. Sucampo lost the arbitration.[3]

In late 2015, the company moved its headquarters from Bethesda, Maryland to Rockville, Maryland.[4]

In January 2016, the company acquired an option for an exclusive license to a drug to treat familial adenomatous polyposis.[5]

In April 2017, the company acquired Vtesse.[6]

In February 2018, the company was acquired by Mallinckrodt. At that time, the founders owned a combined 30% of the company.[7]

References

  1. ^ a b c d "Sucampo Pharmaceuticals, Inc. 2016 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
  2. ^ "FDA Approves New Type of Drug To Treat Constipation in Adults". The Wall Street Journal. February 1, 2006.
  3. ^ Flook, Bill (July 6, 2012). "Sucampo loses arbitration with pharma partner". American City Business Journals.
  4. ^ Proctor, Carolyn M. (May 13, 2016). "3 things you should know about Greater Washington's bioscience companies". American City Business Journals.
  5. ^ Reed, Tina (January 11, 2016). "Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million". American City Business Journals.
  6. ^ "Sucampo Acquires Vtesse Inc" (Press release). Globe Newswire. April 3, 2017.
  7. ^ Reed, Tina (February 13, 2018). "Sucampo Pharmaceuticals closes on its $1.2B sale to a U.K. company". American City Business Journals.
Retrieved from "https://mdwiki.org/wiki/Sucampo_Pharmaceuticals"